Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Processa Pharmaceuticals, Inc. - Common Stock (NQ:PCSA)

0.4331 +0.0370 (+9.34%)
Streaming Delayed Price Updated: 10:44 AM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Processa Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Earnings Scheduled For March 30, 2023
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. 
Via Benzinga
Earnings Preview: Processa Pharmaceuticals
 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Schedules Conference Call/Webinar to Review FY 2022 Results, Discuss Corporate Updates
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 479 stocks made new 52-week lows. 
Via Benzinga
Processa Pharma's Investigational Candidate Improves Gastroparesis-Associated Clinical Symptoms
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Doses First Patient in Key Study of Next-Generation Chemotherapy-Capecitabine
Via Investor Brand Network
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Oppenheimer Healthcare Conference
Via Investor Brand Network
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Prioritizes Development of Next Generation Chemotherapies
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes on $6.25M Registered Direct Offering
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces $6.25M Registered Direct Offering
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning! It's time to start the final day of trading this week with a look at the biggest pre-market stock movers for Friday! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 13 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 22 companies hit new 52-week lows. 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Biotech Showcase
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 75 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 116 companies set new 52-week lows. 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) PCS12852 Demonstrates Clinically Meaningful Improvements in Gastroparesis Symptoms
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Thursday
  Thursday's session saw 329 companies set new 52-week lows. 
Via Benzinga
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial
From Processa Pharmaceuticals, Inc.
Via GlobeNewswire
Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update
From Processa Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.